. It features an array developed at the UCSD with a gold surface that is perforated with nanometre-wide holes. A glycoprotein is attached to the gold surface inside the hole and the pathogen or carbohydrate-binding lectin is added. The instrument detects binding events through surface plasmon resonance (SPR), measuring fluctuations in electron density at the boundary between the metal and a dielectric surface.
Hwang and Mullen use microfluidic delivery channels to place the glycoproteins on the gold surface. When the proteins attach to the gold there is a detectable change in plasmon resonance. Once this reaches equilibrium, the pathogen or lectin is introduced using the delivery channel and any binding that takes place further changes the plasmon resonance. The device is reusable as acids can be used to break the glycanlectin bonds and clean the array.
" "I realized from discussions with other researchers that predictive tools to compute binding affinities between sugars and lectins do not exist today," Hwang says, noting that this is a gap in glycan research tools that does not exist for nucleic acids and proteins. But she thinks in time, as more biophysical information is gained about glycan structures and properties, glycan arrays will catch up.
N.B.
Elizabeth Higgins, chief executive and founder of GlycoSolutions in Worcester, Massachusetts, feels that a different factor is driving the drug industry's interest in glycan analysis. GlycoSolutions offers glycomics services and analyses, and last year worked on 20 different glycosylation analysis projects for various pharmaceutical companies. Higgins says that the analyses were largely done to meet regulatory requirements. "Most companies we work with are driven by getting data for the Food and Drug Administration, " she says.
Another company working on highthroughput tools for analysing glycosylation patterns to aid drug development is Procognia, in Ashdod, Israel. Because many different glycoforms can exist, an extensive knowledge of glycosylation patterns and how they change during drug manufacturing is important for he development of biosimilar drugs, says Ilana Belzer, Procognia's vice-president of research and development. To tackle this issue, the firm has developed GlycoScope, a high-throughput workflow for glycosylation analysis platform that uses lectin (carbohydrate-binding protein) arrays and informatics tools to provide glycosylation fingerprints and glycan structures for glycoproteins.
By providing values of molecular weight that can be used to deduce initial structures, mass spectrometry (MS) is yet another approach to glycan analysis. "MS is very good at defining the sugar profiles of cell surfaces," says James Paulson, a glycobiologist at the Scripps Research Institute who studies glycan binding proteins that mediate cellular communication in the immune system. With additional isolation and fragmentation using either matrix-assisted laser desorption/ionization or electrospray ionization followed by tandem MS (MS/MS), researchers can deconvolute the configuration of sugars, a process very similar to protein sequencing.
The past few years have seen the arrival of many commercial programs and algorithms that assign glycan structures based on MS spectra. PREMIER Biosoft based in Palo Alto, California, sells SimGlycan, which uses MS/ MS data to query a database of more than 8,000 theoretical glycan fragmentation patterns to generate a list of probable structures. Developers at the Palo Alto Research Center have designed new software packages that identify and annotate glycopeptides from a combinaSurface plasmon resonance provides label-free methods to look at carbohydrate interactions.
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